May 26, 2026 · Form 4 insider transaction
Friedman David Matthew bought 35,000 shares of Benitec Biopharma Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as a Managing Director of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital, the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service.; The Options will vest in full on the earlier of immediately prior to the Issuer's next annual meeting of stockholders and May 26, 2027.